Malaria is preventable and treatable, but many children living in Africa die from malaria before their fifth birthday. The ACCESS-SMC project has proven the feasibility, safety and effectiveness of seasonal malaria chemoprevention (SMC) at scale. There is an estimated gap of 12 to 18 million children who could benefit from SMC, but who are not currently included in SMC programmes. It is urgent to close this gap and maximize the impact of this intervention. Malaria can be prevented, and in the Sahel and sub-Sahel regions of Africa SMC can make an important contribution.
« Back to Publications